Korean Market
EXCH
GI Innovation
★

GI Innovation Receives Korean MFDS Approval for Phase 1b/2 Trial of GI-102 + Pasritamig in mCRPC, Adding Major Korean Hospitals and Strengthening Janssen Collaboration

 
EXCH
GI Innovation
★

GI Innovation Announces Administrative Resubmission of IND to FDA Due to Review Division Reassignment... Phase 1b/2 Trial of Combination Therapy with Janssen

 
PERI
GI Innovation
★

GI Innovation: Q1 2026 Operating Loss Widens but Clinical Progress and Strong Cash Position

 
EXCH
GI Innovation
★★

Decision to Cancel Treasury Shares for Shareholder Value Enhancement

 
OTHR
GI Innovation
★

GI Innovation Files Correction Report on Stock Option Grants – Slight Adjustment in Grantees and Shares